International Journal of Medical and Dental Sciences

Vijay Kumar Sehgal ¹, Supratik Das ¹, Anand Vardhan ²

Affiliations
1 Department of Pharmacology, Govt. Medical College, Patiala, Punjab, IN
2 Department of Pharmacology, Andaman and Nicobar Institute of Medical Sciences, Port Blair, IN

Abstract

Designing of drugs and their development are a time and resource consuming process. There is an increasing effort to introduce the role of computational approach to chemical and biological space in order to organise the design and development of drugs and their optimisation. The role of Computer Aided Drug Designing (CADD) are nowadays expressed in Nanotechnology, Molecular biology, Biochemistry etc. It is a diverse discipline where various forms of applied and basic researches are interlinked with each other. Computer aided or in Silico drug designing is required to detect hits and leads. Optimise/ alter the absorption, distribution, metabolism, excretion and toxicity profile and prevent safety issues. Some commonly used computational approaches include ligand-based drug design, structure-based drug design, and quantitative structure-activity and quantitative structure-property relationships. In today's world, due to an avid interest of regulatory agencies and, even pharmaceutical companies in advancing drug discovery and development process by computational means, it is expected that its power will grow as technology continues to evolve. The main purpose of this review article is to give a brief glimpse about the role Computer Aided Drug Design has played in modern medical science and the scope it carries in the near future, in the service of designing newer drugs along with lesser expenditure of time and money.

Keywords

Computer-Aided Drug Design, Structure Based Drug Design, Ligand-Based Drug Design, Pharmacophore Model, Molecular Modelling.

Full Text

   

Supratik Das ¹, Vijay Kumar Sehgal ¹

Affiliations
1 Department of Pharmacology, Govt. Medical College, Patiala, Punjab, IN

Abstract

The World Health Organisation estimates that one-third of the world's population are currently infected with Tuberculosis bacillus, 10% of whom will develop the disease at some point in their lifetime. Poverty-Stricken countries of Africa and Asia bear the brunt of the disease partly due to an ominous synergy between mycobacterium bacteria and HIV. The recent recognition of MDR-TB and strains with more complex resistance patterns has stimulated the development of new TB medications including fluoroquinolones, oxazolidinones, diarylquinolines, nitroimidazopyrans. Delamanid, a newer mycobacterial cell wall synthesis inhibitor, received a conditional approval from European medicines agency (EMA) for the treatment of MDR‑TB. Preclinical and clinical studies have shown that delamanid has high potency, least risk for drug‑drug interactions and better tolerability. The purpoe of this article is to bring forward, the various roles played by Delamanid in order to curb the problem of Multi-drug resistant Tuberculosis.

Keywords

Delamanid, Nitro-Dihydro-Imidozooxazole, Pro-Drug, Multidrug-Resistant Tuberculosis, Mycolic Acid Inhibitor.

Full Text

   

Vijay Kumar ¹, Supratik Das ¹

Affiliations
1 Department of Pharmacology, Govt Medical College, Patiala, IN

Abstract

Lowering blood glucose levels in case of patients suffering from type 1 diabetes plays an important role in decreasing the risk of long-term complications. In clinical scenario, fully fledged insulin therapy is often limited by the increased risk hypoglycemia which is severe in nature. Thus, nowadays newer and safer regimens of oral hypoglycemic drugs are introduced out of which beta 3 adrenergic receptor agonists are showing a promising future in combating the menace of hyperglycemia or diabetes mellitus paired with obesity.

Full Text